Physician profile
Stacy Marsh
NPI 1659433092
$10,722.33
in general payments reported to CMS, 2019-2025
40 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,201 · 2022: $2,711 · 2023: $1,984 · 2024: $1,916 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,628 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,628.04 |
| Education | $182.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,000.42 | 2021-2025 | |
| Novo Nordisk INC | $1,102.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $926.02 | 2021-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $848.03 | 2021-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $821.89 | 2021-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $786.70 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $575.52 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $325.19 | 2021-2024 | Rexulti, Abilify Maintena |
| Phathom Pharmaceuticals, INC. | $274.27 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $272.54 | 2023-2024 | Korlym |
| Amgen INC. | $259.92 | 2021-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $252.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $234.93 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $231.88 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $218.91 | 2023-2025 | Gemtesa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.